

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7214173

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
IPROTEOS S.L	03/07/2022
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ACCURE THERAPEUTICS, S.L.
<b>Street Address:</b>	TORRES R+D+I
<b>Internal Address:</b>	BALDIRI REIXAC, 4-8
<b>City:</b>	BARCELONA
<b>State/Country:</b>	SPAIN
<b>Postal Code:</b>	E-08028
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	10414797
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(908)654-7866
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(908) 654-5000
<b>Email:</b>	assignment@lernerdavid.com
<b>Correspondent Name:</b>	LERNER, DAVID, LITTENBERG, KRUMHOLZ & MENTLIK, LLP
<b>Address Line 1:</b>	20 COMMERCE DR.
<b>Address Line 4:</b>	CRANFORD, NEW JERSEY 07016
<b>ATTORNEY DOCKET NUMBER:</b>	ABG 3.3F-008
<b>NAME OF SUBMITTER:</b>	LIZ SEMON
<b>SIGNATURE:</b>	/Liz Semon/
<b>DATE SIGNED:</b>	03/09/2022
<b>Total Attachments: 1</b>	
source=Assignment (USA) LN signed#page1.tif	

**ASSIGNMENT**

This Assignment is made by and between **Iproteos S.L ("ASSIGNOR")**, a corporation of Spain, having its principal place of business located at Baldiri Reixac, 10 Edificio Cluster I, E-08028 Barcelona, SPAIN and **ACCURE THERAPEUTICS, S.L. ("ASSIGNEE")**, a corporation of Spain, having its principal place of business located at Torres R+D+I, Baldiri Reixac, 4-8, E-08028 Barcelona, SPAIN.

**WHEREAS:**


- A. **ASSIGNOR** is the sole owner in respect of **U.S. Patent No. 10,414,797**, entitled "Gelatinase Inhibitors And Use Thereof," issued on September 17, 2019 (hereinafter "the **ASSIGNED PATENT**"); and
- B. **ASSIGNEE** is desirous of accruing all of the right, title and interest in and to the **ASSIGNED PATENT** and the inventions disclosed therein;

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, **ASSIGNOR** has sold, assigned and transferred, and does hereby sell, assign and transfer to **ASSIGNEE** all right, title and interest in any and all of the following:

- (i) the **ASSIGNED PATENT** and the inventions disclosed therein;
- (ii) all reissues, divisionals, continuations, continuations-in-part, extensions, renewals, reexaminations and foreign counterparts thereof, and other patents, patent applications, certificates of invention other governmental grants resulting from the **ASSIGNED PATENT**;
- (iii) all patents and patent applications which claim priority to or have common disclosure or common priority with any of the **ASSIGNED PATENT**;
- (iv) all rights corresponding to any of the foregoing throughout the world (including the national phase applications of the PCT international applications and the right to claim the priority date of any of the **ASSIGNED PATENT**); and
- (v) the right to sue for and recover damages for any past, present or future infringement of the **ASSIGNED PATENT**, and/or any item in any of the foregoing categories (ii)-(iv).

IN WITNESS WHEREOF, **ASSIGNOR** has caused these presents to be signed by its duly appointed trustee having full authority to convey its property; and **ASSIGNEE** has caused these presents to be signed by its duly appointed trustee.

**Iproteos S.L**  
**ASSIGNOR**


By:   
(Authorized Signature)

Name: Laurent Nguyen  
(Typed or Printed Name)

Title: CEO

Date: March 7 2022

**ACCURE THERAPEUTICS, S.L.**  
**ASSIGNEE**

By:   
(Authorized Signature)

Name: Laurent Nguyen  
(Typed or Printed Name)

Title: CEO

Date: March 7 2022